Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Assessment of Neoantigens for Therapeutic Cancer Vaccines in Li-Fraumeni Syndrome

EF 2024-25

Résumé
Li-Fraumeni Syndrome (LFS) is a cancer predisposition syndrome associated with germline mutations in TP53, a key tumor suppressor gene. These mutations significantly increase the risk of developing a broad range of cancers at an early age. One emerging strategy to improve outcomes for LFS patients is cancer interception, which focuses on detecting and intervening in the early stages of tumorigenesis, ideally before any clinical symptoms appear. Therapeutic vaccines targeting tumor-specific neoantigens offer a potential intervention by stimulating the patient's immune system to identify and destroy cancer cells. Neoantigens are proteins uniquely expressed by tumor cells and absent from normal ones, making them promising targets for immune-based therapies. However, a thorough verification process is required to confirm their immunogenicity and assess potential off-target effects.This project aims to validate neoantigens identified in tumor samples from LFS patients for their suitability as targets in therapeutic cancer vaccines. Key aspects of the project include assessing the immune response to potential neoantigen targets, evaluating off-target effects, and validating findings in a humanized mouse model. Methods include immune activation assays, patient-derived models, flow cytometry, and histological analysis. This work aims to establish a framework for neoantigen assessment for therapeutic vaccines targeting LFS-associated cancers. The project has the potential to improve both the safety and efficacy of immunotherapy, advancing precision oncology for individuals with LFS and other cancer predisposition syndromes.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
530371
Name
Driscoll Madeleine M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Assessment of Neoantigens for Therapeutic Cancer Vaccines in Li-Fraumeni Syndrome
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Genetics; Cancer Interception; Cancer Pre-Disposition; Immunotherapy; Li-Fraumeni Syndrome; Mrna Vaccine; Neoantigens; Oncology; Precision Medicine; Therapeutic Vaccine
Abstract
Li-Fraumeni Syndrome (LFS) is a cancer predisposition syndrome associated with germline mutations in TP53, a key tumor suppressor gene. These mutations significantly increase the risk of developing a broad range of cancers at an early age. One emerging strategy to improve outcomes for LFS patients is cancer interception, which focuses on detecting and intervening in the early stages of tumorigenesis, ideally before any clinical symptoms appear. Therapeutic vaccines targeting tumor-specific neoantigens offer a potential intervention by stimulating the patient's immune system to identify and destroy cancer cells. Neoantigens are proteins uniquely expressed by tumor cells and absent from normal ones, making them promising targets for immune-based therapies. However, a thorough verification process is required to confirm their immunogenicity and assess potential off-target effects.This project aims to validate neoantigens identified in tumor samples from LFS patients for their suitability as targets in therapeutic cancer vaccines. Key aspects of the project include assessing the immune response to potential neoantigen targets, evaluating off-target effects, and validating findings in a humanized mouse model. Methods include immune activation assays, patient-derived models, flow cytometry, and histological analysis. This work aims to establish a framework for neoantigen assessment for therapeutic vaccines targeting LFS-associated cancers. The project has the potential to improve both the safety and efficacy of immunotherapy, advancing precision oncology for individuals with LFS and other cancer predisposition syndromes.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Driscoll, Madeleine M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~